Nektar Therapeutics' eczema drug maintained skin reactions in patients in a one-year study. The study met expectations and in some cases exceeded them. The results demonstrated the maintenance of skin responses throughout the year. These findings were reported as part of the STAT+ program. The drug thus demonstrated long-term effectiveness in the treatment of eczema. Investors had set expectations that were met or exceeded. The study confirmed stable skin reactions without providing specific statistics.